Use access key #2 to skip to page content.
$10.27 -0.63 (-5.78%)
1/9/2009 4:00 PM

Alkermes, Inc. (ALKS)

CAPS Rating:
****

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

View All Commentary (ALKS)

Recs

2

Avatar zzlangerhans (99.34) Submitted: 10/13/08 1:50 PM : Outperform Start Price: $11.96 ALKS Score: 6.11

Risperdal Consta revenues continue to increase and have become the backbone of the franchise. Meanwhile, the stock has been pressured by concerns about the future of Exenatide given the problems with Byetta. I remain bullish on both Alkermes and Amylin, in the belief that the pancreatitis issue will be resolved with additional language on the label and will not result in significantly reduced prescriptions. ALKS 27 and ALKS 29 remain wild cards, having essentially vanished from quarterly statements and press releases.

Report this Post Replies: 1 | Reply | Permalink

Avatar zzlangerhans (99.34) Submitted: 12/20/08 5:37 PM

Recs: 0 | Rec This

Alkermes has entered some shaky territory and I'll take my points here. I have a feeling the recent rise will not be sustained, and I'll try to get back in under 9.

Report this Post Reply

Featured Broker Partners

Sponsored Links